ARROW study: pralsetinib in RET fusion+ tumors
ARROW points the way for RET fusion-positive NSCLC treatment | Stephen LiuПодробнее
ARROW update confirms pralsetinib benefit for RET fusion-positive advanced NSCLC | Stephen LiuПодробнее
Pralsetinib in Chinese patients with advanced RET fusion+ NSCLCПодробнее
ASCO 2021 - Blueprint Medicines - ARROW Study Updated ResultsПодробнее
ARROW: clinical activity of pralsetinib in RET-fusion positive solid tumorsПодробнее
ARROW: an update on the registrational studyПодробнее
ARROW: precision targeted therapy with pralsetinib for RET fusion+ tumorsПодробнее